Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongxian Hu

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Chinese Medical Journal Pulmonary and Critical Care Medicine|January 19, 2026
CAR-T therapy: Advances in respiratory diseasesHui Han, Yongxian Hu
Critical Reviews in Oncology/Hematology|July 10, 2026
Optimizing CAR-T Therapy in Diffuse Large B-Cell Lymphoma: Biological Determinants and Translational Strategies Across the Therapeutic ContinuumYishan Wang, Yongxian Hu
Frontiers in Immunology|March 15, 2021
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic PredictionRuimin Hong, Yongxian Hu, He Huang
Stem Cell Investigation|February 1, 2019
Current development of chimeric antigen receptor T-cell therapyJiasheng Wang, Yongxian Hu, He Huang
Regenerative Therapy|August 2, 2019
Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCTYingying Yang, Yongxian Hu, He Huang
Stem Cell Investigation|February 12, 2021
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myelomaLijuan Ding, Yongxian Hu, He Huang
Journal of Leukocyte Biology|October 12, 2017
Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapyJiasheng Wang, Yongxian Hu, He Huang
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|September 26, 2022
Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphomaShan Fu, Yongxian Hu, He Huang
The New England Journal of Medicine|July 3, 2024
CD7 CAR T-Cell Therapy and Allogeneic HSCT. ReplyYongxian Hu, Dongrui Wang, He Huang
Clinical Transplantation|February 7, 2013
Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysisKaili Du, Yongxian Hu, Kangni Wu, et al.
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Chinese Medical Journal Pulmonary and Critical Care Medicine|January 19, 2026
CAR-T therapy: Advances in respiratory diseasesHui Han, Yongxian Hu
Critical Reviews in Oncology/Hematology|July 10, 2026
Optimizing CAR-T Therapy in Diffuse Large B-Cell Lymphoma: Biological Determinants and Translational Strategies Across the Therapeutic ContinuumYishan Wang, Yongxian Hu
Frontiers in Immunology|March 15, 2021
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic PredictionRuimin Hong, Yongxian Hu, He Huang
Stem Cell Investigation|February 1, 2019
Current development of chimeric antigen receptor T-cell therapyJiasheng Wang, Yongxian Hu, He Huang
Regenerative Therapy|August 2, 2019
Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCTYingying Yang, Yongxian Hu, He Huang
Stem Cell Investigation|February 12, 2021
Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myelomaLijuan Ding, Yongxian Hu, He Huang
Journal of Leukocyte Biology|October 12, 2017
Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapyJiasheng Wang, Yongxian Hu, He Huang
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|September 26, 2022
Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphomaShan Fu, Yongxian Hu, He Huang
The New England Journal of Medicine|July 3, 2024
CD7 CAR T-Cell Therapy and Allogeneic HSCT. ReplyYongxian Hu, Dongrui Wang, He Huang
Clinical Transplantation|February 7, 2013
Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysisKaili Du, Yongxian Hu, Kangni Wu, et al.
Pageof 19